📊 CNTA Key Takeaways
Is Centessa Pharmaceuticals plc (CNTA) a Good Investment?
Centessa is a clinical-stage biopharmaceutical company with severe financial distress, burning through $138M in operating cash annually with only $50.8M in cash reserves, providing minimal runway. The company generated negligible revenue ($15M, down 100% YoY) while operating losses exceeded $139M, indicating it is far from commercialization. With negative operating margins of -928% and free cash flow of -$138.4M, the company faces existential solvency risk without immediate capital raises or transformative value creation.
Centessa Pharmaceuticals shows very weak current fundamentals, with revenue effectively disappearing year over year and operating losses remaining extremely large relative to its revenue base. While the balance sheet is not overleveraged and near-term liquidity appears strong, the company is still consuming substantial cash, so the core fundamental story depends on future pipeline execution rather than present operating strength.
Why Buy Centessa Pharmaceuticals plc Stock? CNTA Key Strengths
- Strong balance sheet composition with $301.6M stockholders' equity and low debt/equity ratio of 0.36x, reducing bankruptcy risk from leverage
- Excellent current and quick ratios (10.57x) indicating sufficient short-term liquidity to meet immediate obligations
- Early-stage pharmaceutical pipeline positioning with 11 Form 4 insider filings suggesting ongoing management activity
- Strong near-term liquidity with current and quick ratios of 10.57x
- Moderate leverage with debt-to-equity of 0.36x and positive equity base of $301.57M
- Net loss improved materially year over year, indicating some cost or expense normalization
CNTA Stock Risks: Centessa Pharmaceuticals plc Investment Risks
- Catastrophic cash burn rate of $138M annually with only $50.8M cash reserves, indicating less than 5 months of runway at current burn rate
- Complete revenue collapse (down 100% YoY) with only $15M recognized, demonstrating failure of commercial efforts or product discontinuation
- Massive operating losses with -928% operating margin and -875% net margin indicating business model is fundamentally broken and unprofitable at scale
- Negative interest coverage ratio of -55x reflects inability to service debt from operations; dependent on cash reserves and capital markets
- Pre-commercial pharmaceutical company facing typical clinical development risk with no approved commercial products generating meaningful revenue
- Revenue declined 100% year over year, highlighting weak and potentially non-recurring commercial or collaboration income
- Profitability remains deeply negative, with operating margin of -928.1% and net margin of -875.8%
- Heavy cash burn with operating cash flow of -$138.01M and free cash flow of -$138.37M raises funding risk if losses persist
Key Metrics to Watch
- Cash burn rate trend and remaining months of runway before insolvency
- Clinical trial progress and potential FDA approvals that could enable revenue generation
- Capital raise announcements and terms that would dilute existing shareholders
- Operating cash flow trajectory and any improvements in cash efficiency
- Quarterly operating cash burn and free cash flow trend
- Revenue durability and pipeline-driven milestone or product revenue conversion
Centessa Pharmaceuticals plc (CNTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.57x current ratio provides a solid financial cushion.
CNTA Profit Margin, ROE & Profitability Analysis
CNTA vs Healthcare Sector: How Centessa Pharmaceuticals plc Compares
How Centessa Pharmaceuticals plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Centessa Pharmaceuticals plc Stock Overvalued? CNTA Valuation Analysis 2026
Based on fundamental analysis, Centessa Pharmaceuticals plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Centessa Pharmaceuticals plc Balance Sheet: CNTA Debt, Cash & Liquidity
CNTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Centessa Pharmaceuticals plc's revenue has grown significantly by 119% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.06 indicates the company is currently unprofitable.
CNTA Revenue Growth, EPS Growth & YoY Performance
CNTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$42.6M | $-0.37 |
| Q2 2025 | N/A | -$43.8M | $-0.38 |
| Q1 2025 | N/A | -$26.1M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Centessa Pharmaceuticals plc Dividends, Buybacks & Capital Allocation
CNTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Centessa Pharmaceuticals plc (CIK: 0001847903)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTA
What is the AI rating for CNTA?
Centessa Pharmaceuticals plc (CNTA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTA's key strengths?
Claude: Strong balance sheet composition with $301.6M stockholders' equity and low debt/equity ratio of 0.36x, reducing bankruptcy risk from leverage. Excellent current and quick ratios (10.57x) indicating sufficient short-term liquidity to meet immediate obligations. ChatGPT: Strong near-term liquidity with current and quick ratios of 10.57x. Moderate leverage with debt-to-equity of 0.36x and positive equity base of $301.57M.
What are the risks of investing in CNTA?
Claude: Catastrophic cash burn rate of $138M annually with only $50.8M cash reserves, indicating less than 5 months of runway at current burn rate. Complete revenue collapse (down 100% YoY) with only $15M recognized, demonstrating failure of commercial efforts or product discontinuation. ChatGPT: Revenue declined 100% year over year, highlighting weak and potentially non-recurring commercial or collaboration income. Profitability remains deeply negative, with operating margin of -928.1% and net margin of -875.8%.
What is CNTA's revenue and growth?
Centessa Pharmaceuticals plc reported revenue of $15.0M.
Does CNTA pay dividends?
Centessa Pharmaceuticals plc does not currently pay dividends.
Where can I find CNTA SEC filings?
Official SEC filings for Centessa Pharmaceuticals plc (CIK: 0001847903) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTA's EPS?
Centessa Pharmaceuticals plc has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CNTA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Centessa Pharmaceuticals plc has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CNTA stock overvalued or undervalued?
Valuation metrics for CNTA: ROE of -43.6% (sector avg: 15%), net margin of -875.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CNTA stock in 2026?
Our dual AI analysis gives Centessa Pharmaceuticals plc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNTA's free cash flow?
Centessa Pharmaceuticals plc's operating cash flow is $-138.0M, with capital expenditures of $360.0K. FCF margin is -922.5%.
How does CNTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -875.8% (avg: 12%), ROE -43.6% (avg: 15%), current ratio 10.57 (avg: 2).